Introduction
The main goal of anticancer therapy is to selectively induce apoptosis in cancer cells while sparing untransformed cells and healthy tissues. One promising approach is triggering of the extrinsic apoptotic pathway by TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), a member of tumor necrosis factor superfamily, which has been shown to selectively induce apoptosis in various cancer cells in vitro and in vivo (1, 2) . The different sensitivity/resistance to TRAIL in normal and cancer cells is still a matter of debates among the experts. Several potential ways of resistance of non-tumorigenic cells to TRAIL have been proposed so far, at the level of both surface and intracellular molecules. Furthermore, many tumor cells have been shown to be resistant to the effects of TRAIL due to deficiencies in apoptotic pathways or over-activated prosurvival signaling (3) (4) (5) (6) . Elucidation of the molecular mechanisms of the resistance and designing safe combination therapy using agents capable of sensitizing the cancer but not normal cells to TRAIL-induced apoptosis are important prerequisites of the successful clinical application of this cytokine.
There are five known types of TRAIL receptors. Death receptors (DRs) DR4 (TRAIL-R1) and DR5 (TRAIL-R2) containing death domain (DD) are responsible for transmission of the apoptotic signal, whereas decoy receptors (DcRs) DcR1 (TRAIL-R3, lacking DD) or DcR2 (TRAIL-R4, with truncated DD) and a soluble receptor osteoprotegerin (TRAIL-R5) are unable to signal apoptosis. However, the cell surface expression of particular TRAIL receptor may not fully correlate with its functional importance in induction/inhibition of TRAIL apoptotic signaling. It has been published in several cancer cell types that despite the presence of both DRs at their surface, particular tumors preferentially signal through either DR4 (e.g. lymphocytic leukemia) (7) or DR5 (e.g. colon cancer) (8) . The specific DR involvement as well as differences in apoptotic signaling mediated by DR4 or DR5 remain to be answered. Some authors also showed a higher expression of DcRs in non-tumorigenic compared with tumor cells. However, this phenomenon may be tissue specific, and the sole presence of surface DcRs has often been found not sufficient to protect the cells from apoptotic effect of TRAIL (9, 10) .
DR4 and DR5 mediate TRAIL-induced apoptosis by recruiting Fas-associated DD protein and pro-caspase-8 to form a deathinducing signaling complex (DISC). The amount of caspase-8 activated at the DISC is important factor affecting further progression of apoptotic signaling. In so-called type I cells, abundantly activated caspase-8 directly cleaves and activates effector caspases, which leads to execution of cell death. In type II cells, the amount of caspase-8 activated at the DISC is not sufficient to trigger an adequate effector caspase stimulation; therefore, amplification of the apoptotic signal via mitochondria is required (11, 12) . In this case, a BH-3-only protein Bid is cleaved by caspase-8 to tBid and translocated to mitochondria to trigger processes leading to release of proapoptotic proteins such as cytochrome c into the cytosol (12) . Cytochrome c, Apaf-1 and procaspase-9 then form an apoptosome complex where caspase-9 is activated, and the apoptotic signal is augmented.
The initial steps of TRAIL signaling have been studied intensively, especially the regulation of TRAIL receptor expression, their translocation to the cell surface, plasma membrane distribution, lipid raft (co)localization and receptor internalization (endocytosis). Lipid rafts are dynamic plasma membrane microdomains enriched with cholesterol and sphingolipids. They play fundamental roles in diverse cellular processes, particularly in signal transduction, by promoting compartmentalization of membrane proteins and lipids (13, 14) . Recent studies have suggested the role of lipid rafts as platforms for DRmediated apoptosis signaling (15) . Relocalization of TRAIL DRs into the lipid rafts has been shown to facilitate DISC formation and caspase-8 activation-initiated apoptosis, whereas TRAIL-DISC assembly in the non-raft phase of the plasma membrane resulted in inhibition of caspase-8 cleavage and a promotion of antiapoptotic signaling (15) . Changes of the DRs distribution within the plasma membrane may therefore have a crucial impact on modulation of cell sensitivity/resistance to apoptotic signals triggered by TRAIL. Death ligand-receptor interactions may induce receptor clustering and internalization, which targets the active receptor to endocytic compartments. An essential requirement for receptor internalization in transmitting the CD95L-induced apoptotic signal has been reported (16, 17) . In contrast, although being rapidly internalized, TRAIL and its DRs have been reported not to essentially require internalization for DISC formation, caspase-8 activation and subsequent apoptosis induction in BJAB type I cells (18) .
Combined treatment with chemotherapeutic drugs has been shown to overcome TRAIL resistance in many cancer cell types. Diverse molecular mechanisms have been reported to be responsible for synergistic effects of these agents to induce apoptosis of target cells. Chemotherapy may have a great impact on the crucial steps of the TRAIL signaling pathway, e.g. through increase of TRAIL DR expression (19, 20) , lipid raft relocalization (21, 22) , decrease of cellular FLICE-like inhibitory protein level (23) , facilitating DISC formation and caspase-8 activation (24) , upregulation/downregulation of proapoptotic/antiapoptotic molecules (25) or stimulation of mitochondria (26) . The involvement of the particular events depends on the type and/or stage of cancer, type I/II cells and the type of the selected chemotherapeutic drug(s).
Platinum complexes, e.g. cisplatin, carboplatin and oxaliplatin, belong to the most widely used chemotherapeutic agents in the treatment of solid cancers. By creating covalent bonds with DNA, they induce DNA damage signaling, which leads either to cell cycle arrest providing time to repair the damage or to immediate activation of apoptotic signaling via the intrinsic mitochondrial pathway and killing of cancer cells. However, application of therapy using platinum drugs such as cisplatin is limited due to serious side effects and/or development of intrinsic or acquired resistance of the cancer cells. In the past two decades, plenty of newly synthesized analogues of platinum complexes were examined and some of them entered the clinical trials, e.g. Pt(IV) complexes. LA-12 is a novel Pt(IV) adamantylamine ligand-containing complex, currently in phase I of clinical trials. It has been shown to be more cytotoxic than satraplatin and to efficiently induce cell death in a panel of 14 cancer cell lines with various sensitivity to cisplatin (27) and in ovarian carcinoma cells with acquired (A2780cis) or intrinsic resistance to cisplatin (SK-OV-3) (28, 29) . LA-12 has been shown to induce cell cycle arrest and apoptosis in various cancer cells (30) (31) (32) (33) .
In vivo studies in murine xenografts revealed a higher antitumor activity of LA-12 compared with cisplatin and Pt(IV) complex satraplatin and enhanced tissue penetration and lower acute systemic toxicity. Due to its improved lipophilicity, LA-12 was shown to effectively penetrate tissues and tumors and can be administered perorally (34) (35) (36) . Taken together, these data imply that LA-12 is a promising candidate for cancer therapy, with high effectivity in killing cancer cells in vitro and in vivo and low toxic side effects in vivo.
In the present study, we investigated the role of a novel platinum drug LA-12 in modulation colon and prostate cancer cell sensitivity to apoptotic effects of TRAIL and compared the LA-12-mediated effects with those exerted by conventionally used cisplatin in combination with TRAIL. The molecular mechanisms responsible for the enhancement of apoptosis following combined treatments with these agents were investigated, with special focus on the most upstream events of the TRAIL signaling pathway, namely TRAIL DRs and initiator caspase-8. Both platinum complexes increased DR5 surface expression and lipid raft localization and consequentially TRAIL-induced caspase-8 activation and apoptosis, which could be counteracted by small interfering RNA (siRNA)-mediated DR5 silencing. Our results demonstrate that modulation of the initial steps of the extrinsic apoptotic pathway by LA-12 and cisplatin at the level of DR5 and plasma membrane are important events in sensitization of colon and prostate cancer cells to TRAIL-induced apoptosis.
Materials and methods

Materials and reagents
The stock solutions of cisplatin [cis-diamminedichloroplatinum(II); FW 300.1] (Sigma-Aldrich Corporation, St Louis, MO) and LA-12 [(OC-6-43)-bis (acetato)(1-adamantylamine)ammine dichloroplatinum(IV); FW 552.4] (PlivaLachema a.s., Brno, Czech Republic) were freshly prepared before use. Human N-terminally His-tagged recombinant Apo2L/TRAIL (amino acids 95-281) was affinity-purified from cell lysates of the producer bacteria (Escherichia coli, strain BL-21) and contaminating bacterial endotoxins were removed by Endotrap chromatography (Profos AG, Regensburg, Germany) (37).
Cell culture
The human colon adenocarcinoma HCT-116 (obtained from Prof. B. Vogelstein) and prostate cancer PC-3 (from American Type Culture Collection, LGC Standards Sp. z.o.o., Poland) epithelial cell lines were maintained in McCoy's 5A-modified medium with 1.5 mM L-glutamine (Sigma-Aldrich Corporation) or F12, respectively, supplemented with penicillin (100 U/ml) and streptomycin (0.1 mg/ml) (PAA, Pasching, Austria), sodium bicarbonate (1.5 g/l; Serva, Heidelberg, Germany) and 10% heat-inactivated fetal bovine serum (HCT-116) or 10% fetal bovine serum (PC-3) (PAA, Pasching, Austria). The cells were incubated in a humidified incubator at 37°C in a 5% CO 2 atmosphere and passaged twice a week by ethylenediaminetetraacetic acid/ phosphate-buffered saline (PBS) washing and trypsinization.
WST cytotoxicity assay HCT-116 and PC-3 cells were seeded in 96-well plates in a density of 20 000 cells/cm 2 . After 24 h (HCT-116) or 48 h (PC-3), the cells were treated with cisplatin (10 lM) or LA-12 (0.5 lM). Twenty-four hours later, various amounts of TRAIL (6.25-100 ng/ml) were added. After 24 h of incubation, tetrazolium salt (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) (WST-1) with 1-methoxy-5-methylphenazium methylsulphate (Serva) was added for 4 h and absorbance of a soluble formazan compound formed by metabolically active cells was analyzed using a microplate reader FLUOS-TAR Galaxy (BMG Labtechnologies GmbH, Offenburg, Germany).
Real-time cell impedance analysis
Acea E-platesÒ 96 and an xCELLigence RTCA SP system including RTCA Software v1.2 (both Roche Applied Science, Prague, Czech Republic) monitors cellular events including cell number, adhesion, viability and morphology and provides information about the biological status of the cells in real time by measuring electrical impedance across microelectrodes integrated on the bottom of its special tissue culture plates (38) . First, a standard background measurement was performed using 100 ll of complete culture media. PC-3 cells were trypsinized, counted and seeded in additional 100 ll of culture media in a final concentration of 30 000 cells/cm 2 . The cells were monitored continually every hour after the seeding for a period of 48 h. Next, the cells were pretreated with cisplatin or LA-12 for 24 h followed by treatment with TRAIL (HCT-116 cells: 100 ng/ml, PC-3 cells: 12.5 ng/ml) for another 20 h. During TRAIL treatment, the cells were monitored continually every 2 min in the first 3 h and then every 30 min. Acea E-platesÒ 16 and xCELLigence RTCA DP Analyzer were used for monitoring the effects of tested compounds after transfection with nontargeting siRNA (sc-37007) or siRNA targeting DR5 (sc-40237; both Santa Cruz Biotechnology, Santa Cruz, CA). Briefly, HCT-116 cells were seeded in 200 ll of cultivation media without antibiotics in a final concentration of 50 000 cells/cm 2 and after overnight incubation, the cells were transfected with control or DR5 siRNA using Lipofectamine TM 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Twenty-four hours later, the cultivation medium was replaced by a fresh onewith penicillin/streptomycin and the cells were treated with LA-12 (0.5 lM) for 24 h. Finally, TRAIL (50 ng/ml) was added. During TRAIL treatment, the cells were monitored continually every 2 min for 4 h.
Flow cytometric analysis of TRAIL receptors on the cellular surface
After 24 h of incubation with cisplatin (10 lM) or LA-12 (0.5 lM), the attached cells were harvested by gentle trypsinization, washed twice in cold PBS with 0.2% bovine serum albumin and then incubated with anti-DR4 (#HS101, 1:100), anti-DR-5 antibody (#HS201, 1:100, both fluorescein isothiocyanate-conjugated; Alexis Biochemicals Corporation, Lausen, Switzerland) or anti-DR4 (anti-CD261, #1P-403-C025) and anti-DR5 (anti-CD262, #1P-461-C025; both phycoerythrin-conjugated; Exbio, Vestec, Czech Republic) on ice in the dark for 45 min. The cells were washed twice, and 7-AAD or LIVE/DEADÒ Fixable Dead Cell Stain Far Red (Invitrogen) were added. After 20 min, the expression of DR4 and DR5 was assessed by flow cytometry (FACSCalibur; Becton Dickinson, San Jose, CA). CellQuest Pro software was used for data acquisition and analysis. Dead cells (7-AAD or Dead Cell Stain positive) were excluded from analysis. Receptor expression on the cellular surface was expressed as a ratio of the median fluorescence index of the specific antibody and median fluorescence index of the isotype control antibody. To minimize the possibility of antibody-receptor complex internalization during the incubation period, we performed a staining protocol based on only 10 min of incubation with both antibody and viability probe together. Both analyses gave similar results.
Internalization of TRAIL TRAIL was labeled using Alexa Fluor 647 Microscale Protein Labeling Kit (A30009; Molecular Probes, Eugene, OR) based on the manufacturer's instructions. Cells were seeded in a 12-well plate, incubated with cisplatin (10 lM) or Cisplatin and LA-12-mediated enhancement of TRAIL-induced apoptosis After three washing steps in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, the cells were incubated in ethylenediaminetetraacetic acid/PBS and briefly trypsinized. Trypsin was neutralized by 2% bovine serum albumin in PBS. The cells were centrifuged, resuspended in 2% bovine serum albumin, stained with propidium iodide (5 lg/ml) and immediately analyzed by flow cytometer (18) . The data were analyzed using CellQuest software. Doublets, debris and dead cells (propidium iodide positive) were excluded from analysis.
Western blot analysis
The cells were harvested, washed twice in cold PBS and lysed in 1% sodium dodecyl sulfate buffer and western blot analysis was performed as described previously (30) . Immunodetection was carried out with the following antibodies: anti-DR5 (1:1000, 210-743; Alexis Biochemicals Corporation), caspase-8 (1:500, 9746; Cell Signaling Technology, Danvers, MA), caspase-3 (1:500, sc-7272), Poly(ADP-ribose) polymerase (PARP) (1:500, sc-7150), lamin B (1:500, sc-6217) (all of them Santa Cruz Biotechnology), anti-DR4 (D3813, 1:500) and b-actin (A5441, 1:5000) (both Sigma-Aldrich Corporation). Densitometric quantification of the visualized bands was performed by ImageJ software (National Institutes of Health, Bethesda, MD) and normalized to the expression of b-actin. Immunofluorescent-labeling TRAIL receptors and lipid rafts PC-3 and HCT-116 cells were seeded in IBIDI 8-well coverslip chambers. The cells were washed three times in ice-cold 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer and incubated with 15 lg/ml anti-DR4 (MA1-19025) or anti-DR5 (MA1-19416; Affinity Bioreagents, Golden, CO) monoclonal antibodies for 10 min on ice. After three washes, Alexa Fluor 488-conjugated secondary antibody (A-11017; Molecular Probes) was added at 10 lg/ml together with 4 lg/ml Alexa Fluor 647-conjugated cholera toxin B-subunit (C-34778; Molecular Probes) for 10 min on ice. After three washes, the cells were fixed with 4% formaldehyde and mounted with Mowiol 4-88 (Calbiochem, Darmstadt, Germany). The cholera toxin B-subunit binds to monosialotetrahexosylganglioside (GM1) glycosphingolipid rich domains and serves as one of the most widely used markers for lipid rafts.
Confocal laser scanning microscopy
Confocal laser scanning microscopy (Zeiss LSM 510) was used for colocalization measurements. Alexa Fluor 488 was excited at 488 nm, and Alexa Fluor 647 was excited at 633 nm. Their fluorescence emission was detected through 505-550 nm band-pass filter and 650 nm long-pass filter, respectively. The images were taken in multitrack mode to completely exclude channel cross talk (although the great spectral separation minimized this already). The 512 Â 512-pixel, 1.5 lm thick optical sections were obtained with a Â40 C-Apochromat water immersion objective (NA 5 1.2).
Determining colocalization from image cross-correlation
Colocalization of molecules at the few-hundred-nanometer scale was determined from confocal laser scanning microscopy images of double-labeled cells. The optical section was taken from the top horizontal slice of the membrane of adherent cells. The images were gated on the presence (abovebackground intensity) of at least one of the fluorophores. For a pair of images, x and y, the cross-correlation coefficient between the intensity distributions of cell surface labeling was calculated as (1),
where x ij and y ij are fluorescence intensities at pixel coordinates i, j in images x and y and AExae, AEyae are the mean intensities in each channel. The theoretical maximum is C 5 1 for identical images and a value of 0 implies independent random localization of the labeled molecules. A custom program was written in LabView to analyze the images. The average intensity of labels in the membrane was also evaluated by the program (13, 14) .
RNA interference
HCT-116 cells were seeded at a density of 20 000 cells/cm 2 and cultured for 12 h. Transfections were carried out in McCoy's medium without antibiotics using a Lipofectamine TM 2000 transfection reagent (Invitrogen) according to the manufacturer's protocol. The siRNA targeting DR5 (40 nM; sc-40237) or nontargeting control siRNA (40 nM; sc-37007; Santa Cruz Biotechnology) was added directly to the transfection reagent solution and cells were incubated for 24 h. After the transfection, the medium was replaced by McCoy's medium.
Caspase activity assay
The cells were collected and caspase activity assay was performed as described previously (40) using fluorogenic caspase-8 substrate Ac-IETD-AMC (ALX-260-042-M005; Alexis Biochemicals Corporation).
Statistical analysis
The data were expressed as means ± SDs and analyzed by analysis of variance followed by a Tukey's test or by a nonparametric Mann-Whitney U-test. A P value of ,0.05 was considered significant. All statistical analyses were performed by the Statistica for Windows software, V. 6.1 (StatSoft, Tulsa, OK). Cisplatin and LA-12-mediated enhancement of TRAIL-induced apoptosis
Results
LA-12 or cisplatin enhanced cytotoxic effects of TRAIL in HCT-116 and PC-3 cell lines
After pretreatment with cisplatin (10 lM) or LA-12 (0.5 lM), the cytotoxic effects of TRAIL (6.25-100 ng/ml) were significantly enhanced as demonstrated by a decrease of HCT-116 and PC-3 cell metabolic activity (WST test; Figure 1a , b, e and f). Platinum drugmediated sensitizing effects were clearly evident already when combined with the lowest concentration of TRAIL (6.25 ng/ml). Using a real-time impedance analysis (system xCELLigence; Figure 1c , d, g and h), we also demonstrated a significant decrease of cell surface adhesion following the combined treatment with cisplatin/LA-12 and TRAIL in both cell lines. The pretreatment with platinum drugs prevented recovery of the cell index value observed in cells treated with TRAIL alone.
LA-12-or cisplatin-mediated potentiation of TRAIL-induced cytotoxicity is associated with activation of the apoptotic caspase cascade In order to examine whether the cytotoxicity induced by combination of platinum drugs and TRAIL occurred via activation of the caspase cascade and apoptotic signaling, analysis of the cleavage of caspase-8, -3 and effector caspase substrate PARP was performed (western blotting). Pretreatment with cisplatin or LA-12, followed by TRAIL, resulted in a substantial potentiation of specific processing of pro-caspase-8, -3 and PARP in HCT-116 cells (Figure 2a ) compared with TRAIL alone-treated cells. A similar increase in cleavage of pro-caspase-8 and -3 was also observed in PC-3 cells following combined treatments (Figure 2b) . A corresponding significant increase in the number of cells with characteristic apoptotic changes of nuclear morphology (condensation and fragmentation of chromatin, fluorescence microscopy) was also detected in cisplatin/LA-12 and TRAIL-treated cells compared with the agents used alone (data not shown).
LA-12 and cisplatin were responsible for significant increase of surface DR5 expression in HCT-116 but not in PC-3 cells LA-12 or cisplatin induced a significant concentration-dependent upregulation of the surface DR5 but not DR4 level in HCT-116 cells (Figure 3a) . Increased surface expression of DR5 following treatment with platinum drugs in HCT-116 was also confirmed by confocal microscopy (data not shown). No significant effects of any platinum drug in concentrations used on DR4 and DR5 surface levels were detected in PC-3 cells using flow cytometric analysis (Figure 3b ). LA-12-mediated changes of DR5 surface level in HCT116 cells were accompanied by an increase in DR5 messenger RNA (mRNA) (Figure 3c ) and total protein level (Figure 3d ). Similarly, cisplatin enhanced amounts of DR5 mRNA (Figure 3c ) and total protein (Figure 3d ) in HCT-116 cells. None of the two platinum complexes modulated total amount of DR4 protein in HCT-116 cells (Figure 3d) . Lipid raft localization of DR4 and especially of DR5 was increased upon treatment with cisplatin derivatives To determine the membrane domain localization of DR4 and DR5 with respect to lipid rafts, the receptors on the cell surface were labeled with indirect immunofluorescence (specific monoclonal primary antibodies followed by Alexa Fluor 488 secondary Abs) and CTX B was used as a lipid raft marker specific to GM1-rich domains. The extent of colocalization was quantitated by calculating the Pearson's correlation coefficient from confocal microscopic optical sections of upper horizontal membrane layers from numerous single cells. Both TRAIL DR4 and DR5 receptors colocalized with GM1-rich domains in the plasma membrane of PC3 as well as HCT-116 cells. An example is shown for DR5 in HCT-116 cells (Figure 4a-c) . After 1 h of cisplatin or LA-12 treatment, the colocalization between lipid rafts and TRAIL receptors increased in both HCT-116 (Figure 4d ) and PC-3 cells (Figure 4e ). This effect was more pronounced for DR5.
Cisplatin induced an increase of TRAIL internalization in both PC-3 and HCT-116 cell lines, whereas LA-12 was only effective in the latter one Following treatment with TRAIL, an acute time-dependent increase of dye-conjugated TRAIL internalization was detected in both HCT-116 and PC-3 cell lines by flow cytometry. Suppression of TRAIL internalization by sucrose was used as a negative control of clathrin-dependent endocytosis (18) . Pretreatment with cisplatin resulted in a significant enhancement of TRAIL internalization, starting from 10 or 20 min of subsequent TRAIL treatment in PC-3 or HCT-116 cells, respectively (Figure 5a and b) . LA-12-mediated stimulation of TRAIL internalization was detected only in HCT-116 cells following 30 min incubation with TRAIL (Figure 5a ).
LA-12 or cisplatin-mediated increase of DR5 is essential for potentiation of TRAIL-induced caspase-8 activation and apoptosis in HCT-116 cells To determine the functional role of DR5 in the LA-12/cisplatin and TRAIL-induced apoptosis, the expression of DR5 was downregulated using specific siRNA. Transfection of HCT-116 cells with DR5 but not control siRNA resulted in a significant decrease of basal (72%) as well as LA-12/cisplatin-induced (78/80%) surface level of DR5 (Figure 6a ). Following DR5 siRNA transfection, LA-12/cisplatinmediated stimulation of TRAIL-induced caspase-8 processing/ activation and apoptosis (demonstrated by PARP and lamin B cleavage) was significantly reduced (Figure 6b and c) compared with control siRNA-transfected cells. To further elucidate the role of DR5 in LA-12/cisplatin-enhanced TRAIL-mediated cell death, the cell index was assessed using the xCELLigence system (Figure 6d ). Silencing of DR5 significantly rescued the reduction of the cell index observed in TRAIL-and LA-12/TRAIL-treated cells. The results Cisplatin and LA-12-mediated enhancement of TRAIL-induced apoptosis imply that cisplatin-or LA-12-mediated enhancement of TRAIL-induced cell death depends on DR5 function.
Discussion
The ability to induce apoptosis in tumor cells while sparing nontransformed cells designates TRAIL for the therapy of cancer diseases. Unfortunately, an increasing number of studies demonstrate that many primary tumors are resistant to TRAIL monotherapy (41) . A promising strategy to overcome the resistance of cancer cells and improve the clinical outcome is represented by combination therapy. By this time, combinations of TRAIL with many other antitumor agents with various mechanisms of action including DNA damage have been tested (42, 43) . However, detailed description of the molecular mechanisms of combined effects of these compounds has to precede their possible clinical application. Chemotherapy-mediated enhancement of TRAIL toxicity in tumor cells has been shown to be regulated at many levels, e.g. TRAIL receptors expression and localization, DISC components expression and modulation of their assembly, integrity of mitochondria, prosurvival and apoptotic signaling. Interactions of extrinsic and intrinsic pathways of apoptosis may also be profitable for the killing of type II cells as they rely on the mitochondrial loop to activate enough effector caspases and commit TRAIL-mediated programmed cell death. In our study, we showed that pretreatment with subtoxic concentrations of cisplatin and novel Pt(IV) complex LA-12 significantly enhanced TRAIL-induced apoptosis in human colon and prostate carcinoma cells and we studied molecular mechanisms responsible for the observed effects.
Cisplatin has been shown to enhance the killing capacity of TRAIL in several cancer cell lines in in vitro (19, 20, 44, 45) , in vivo (46, 47) and in ex vivo models (48) . Contradictory studies demonstrating a cisplatin-mediated inhibition of TRAIL-induced cell death through direct inactivation of caspases have also been reported. The authors explain the discrepancy in their results compared with the majority of literature by the dependance on the duration of the treatment (49, 50) . In our study, cisplatin was responsible for significant potentiation of TRAIL-induced apoptosis in human prostate and colon cancer cell lines. Importantly, similar effects on TRAIL-induced apoptosis were also induced by novel Pt(IV) complex LA-12, although a 20-fold lower dose of LA-12 was used compared with cisplatin. The ability of LA-12 to be effective in significantly lower doses when compared with other conventional therapeutic drugs, together with its favorable pharmacokinetic profile, make LA-12 a promising candidate for combination cancer therapy. Enhancement of cell death induction following cisplatin/LA-12 and TRAIL was confirmed by cytotoxic tests, the state-of-the-art noninvasive real time cell impedance analysis method and biochemical and morphological apoptosis assays.
The death domain-containing receptors DR4 and DR5 are important mediators of TRAIL proapoptotic signaling. Modulation of their surface expression may affect the apoptotic signal transduction and sensitivity/resistance of tumor cells to TRAIL-induced apoptosis. Some antitumor agents have been shown to increase expression of DRs at the level of transcription, translation or posttranslational modifications. This increase may result in enhanced sensitivity to TRAIL, while evidence exists that in some models, cisplatin enhanced TRAIL-induced apoptosis without modulation of DRs expression (51, 52) . Cisplatin has been shown to increase expression of TRAIL receptors DR4 or DR5 in esophageal and osteosarcoma tumor cells at the mRNA level (19, 20) . Various mechanisms of regulation of DRs by chemotherapeutic drugs have been suggested. In addition to p53, other transcription factors such as nuclear factor-kappa B or Sp-1 have been demonstrated to be involved in the regulation of DR5 expression (53, 54) . In our study, cisplatin as well as Pt(IV) complex LA-12 increased the expression of DR5 mRNA and protein and enhanced its surface level in colon but not in prostate carcinoma cells. At the same time, these agents were not effective in modulating DR4. The precise mechanisms responsible for cisplatin/LA-12-mediated increase of the DR5 level in HCT-116 cells remain yet to be fully elucidated. We confirmed a functional role of DR5 in LA-12/ cisplatin-mediated enhancement of TRAIL-induced apoptosis in colon cancer cells by showing that siRNA-mediated silencing of the DR5 surface level rescued cells from activation of caspase-8 and apoptosis induced by combination treatment. This implies that DR5 plays an important role in cisplatin/LA-12-mediated enhancement of TRAIL-induced apoptosis, being more important than DR4.
Localization of TRAIL receptor complexes in the plasma membrane and their distribution in membrane microdomains can have a significant functional impact on TRAIL signaling. Cisplatin has been shown to relocalize Fas receptors to lipid rafts and to enhance receptor clustering and apoptosis (55) . The shift of DRs to lipid rafts facilitated the apoptotic outcome of TRAIL by depsipeptide, quercetin and oxaliplatin (21, 22, 56) . LA-12/cisplatin-mediated relocalization of DR4 and DR5 to lipid microdomains was also observed in our models of colon and prostate carcinoma cells. We suggest that in addition to the increase in surface DR levels, changes in lipid rafts localization of DR4 and DR5 may be important in LA-12/cisplatinmediated reinforcement of TRAIL-induced apoptosis.
After the binding of death ligands to their cognate DRs, complexes of ligand and membrane receptors can be internalized via endocytosis. Internalization of Fas receptor (CD95) has been shown to be crucial for Fas ligand-mediated formation of the DISC complex and induction of apoptosis. Inhibition of Fas internalization activated the prosurvival extracellular signal-regulated kinase and nuclear factorkappa B signaling pathways (17) . The role of internalization of the TRAIL ligand and receptor complex for TRAIL-induced apoptosis has not been fully resolved yet. Internalization was described not to influence formation of DISC and activation of caspase-8 in a type I BJAB Burkitt lymphoma B cell line (18) . Nevertheless, transit of TRAIL to lysosomes was shown to contribute to TRAIL-induced apoptosis in the type II hepatocellular carcinoma cell line Huh-7 (57) and to participate in the activation of the lysosomal pathway of apoptosis. Internalization of TRAIL led to release of cathepsin B from lysosomes and liberalization of cytochrome c from mitochondria (58) . Here, we demonstrated that cisplatin-and LA-12-mediated enhancement of TRAIL-induced apoptosis was accompanied by accelerated internalization of TRAIL, suggesting its possible role in the effects observed.
We demonstrated that cisplatin-and the novel platinum(IV) complex LA-12-mediated enhancement of TRAIL-induced apoptosis in human colon and prostate carcinoma cells were associated with modulation of upstream events of TRAIL signaling. Cisplatin and LA-12 increased the expression of DR5, stimulated the relocalization of DR4 and DR5 to lipid rafts and accelerated the internalization of TRAIL. Furthermore, these drugs enhanced TRAIL-induced caspase-8 activation, cleavage of caspase-3 and its substrate PARP and, overall, the fraction of apoptotic cells. We demonstrated a functional role of DR5 in the reinforcement of TRAIL-activated apoptosis by cisplatin and LA-12. Our results show the complexity of interactions of signaling pathways triggered by TRAIL and cisplatin or LA-12 and highlight the striking ability of LA-12 to sensitize the cancer cells to TRAIL-induced apoptosis even when applied in significantly lower doses compared with cisplatin. Our observation will help to improve therapeutical approaches to cancer diseases in terms of more efficient killing of cancer cells, while minimizing the side effects of the therapy. 
